PORTLAND, Ore.--(BUSINESS WIRE)--Aug. 9, 2006--AVI BioPharma, Inc. (Nasdaq:AVII - News) today announced the publication of positive preclinical results from a new class of antisense-based antibiotics, called NeuBiotics. The article, titled "Gene-Specific Effects of Antisense Phosphorodiamidate Morpholino Oligomer-Peptide Conjugates on Escherichia coli and Salmonella enterica Serovar Typhimurium in Pure Culture and in Tissue Culture," appears in the August issue of the journal Antimicrobial Agents and Chemotherapy, Vol. 50, No. 8, p. 2789-2796. AVI research scientists Bruce Geller, Ph.D., and Lucas Tilley authored the paper.
